References
- Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634. https://doi.org/10.1111/j.1538-7836.2007.02374.x
- Lee KW, Bang SM, Kim S, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 2010;8: 540-547. https://doi.org/10.1111/j.1538-7836.2009.03731.x
- Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-464. https://doi.org/10.1001/archinte.166.4.458
- Choi S, Lee KW, Bang SM, et al. Different characteristics and prognostic impact of deep-vein thrombosis / pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients. Thromb Haemost 2011;106:1084- 1094. https://doi.org/10.1160/TH11-07-0505
- Sun JM, Kim TS, Lee J, et al. Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. Lung Cancer 2010;69:330-336. https://doi.org/10.1016/j.lungcan.2009.11.015
- Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-494S. https://doi.org/10.1378/chest.11-2301
- Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153. https://doi.org/10.1056/NEJMoa025313
Cited by
- Risk Factors Associated with Venous Thromboembolism in Cancer Patients vol.15, pp.3, 2013, https://doi.org/10.5388/aon.2015.15.3.171